FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said